Overview

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC®,
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
rimabotulinumtoxinB